0001564590-21-041588.txt : 20210805 0001564590-21-041588.hdr.sgml : 20210805 20210805161129 ACCESSION NUMBER: 0001564590-21-041588 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210805 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210805 DATE AS OF CHANGE: 20210805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kura Oncology, Inc. CENTRAL INDEX KEY: 0001422143 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37620 FILM NUMBER: 211148278 BUSINESS ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 500-8800 MAIL ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE, SUITE 400 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP III DATE OF NAME CHANGE: 20071227 8-K 1 kura-8k_20210805.htm 8-K kura-8k_20210805.htm
false 0001422143 0001422143 2021-08-05 2021-08-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2021

 

KURA ONCOLOGY, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37620

61-1547851

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

12730 High Bluff Drive, Suite 400, San Diego, CA

 

92130

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 500-8800

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

KURA

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


 

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2021, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2021 and providing a corporate update. A copy of this press release is furnished herewith as Exhibit 99.1.

The information contained in this Current Report on Form 8-K under Item 2.02 and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

 

Description

99.1

 

Press release dated August 5, 2021

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

KURA ONCOLOGY, INC.

 

 

 

 

Date: August 5, 2021

 

By:

/s/ Marc Grasso, M.D.

 

 

 

Marc Grasso

 

 

 

Chief Financial Officer and Chief Business Officer

 

 

 

EX-99.1 2 kura-ex991_6.htm EX-99.1 kura-ex991_6.htm

 

Exhibit 99.1

 

 

 

Kura Oncology Reports Second Quarter 2021

Financial Results

 

– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 –

 

– Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in HNSCC –

 

– KO-2806 nominated as lead development candidate in next-generation farnesyl transferase inhibitor program –

 

– $567.5 million in cash, cash equivalents and investments provide runway into 2024 –

 

– Management to host webcast and conference call today at 4:30 p.m. ET –

 

SAN DIEGO, August 5, 2021 – Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2021 financial results and provided a corporate update.

 

“I am extremely proud of the progress our team has made over the past several months, underscoring our focus on operational execution,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.We continue to have strong conviction in KO-539 and its potential to be both a first-in-class and a best-in-class menin inhibitor. This confidence is supported by clinical data from KOMET-001, our Phase 1/2 trial of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML). Given the wide therapeutic window KO-539 demonstrated in the Phase 1a dose escalation portion of the trial, we have now advanced into the Phase 1b expansion cohorts in patients with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML. The Phase 1b enables us to refine the selection of a recommended Phase 2 dose while maintaining an aggressive development timeline for the program.”

 

“Although it is early and the results are still preliminary,” continued Dr. Wilson, “we are encouraged by observations of early signs of clinical activity in the Phase 1b expansion cohorts. We are also encouraged by the rate of patient screening and enrollment, an indication of the enthusiasm of the investigators as well as the strong execution of our clinical operations team. We intend to provide an update on both the Phase 1a and the Phase 1b at a future medical meeting, pending determination of the recommended


 

Phase 2 dose. In the meantime, we look forward to providing qualitative updates on the progress of the Phase 1b in the months ahead.

 

Recent Highlights

 

First patients dosed in Phase 1b expansion cohorts with KO-539 – In late June, Kura announced that the first patient was dosed in the Phase 1b portion of KOMET-001. Patients are now enrolled in each of the two expansion cohorts – a lower dose of 200 mg and a higher dose of 600 mg – each comprising NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients. The Company expects to complete enrollment of 12 evaluable patients in each cohort by the first quarter of 2022, then will assess those patients for safety and tolerability, pharmacokinetics and efficacy in order to determine the recommended Phase 2 dose.

 

Multiple expansion opportunities in acute leukemias – Pending determination of a recommended Phase 2 dose, Kura is preparing to conduct a comprehensive clinical development plan for KO-539, aimed at broadening the opportunity in acute leukemias. Additional development opportunities include combination studies, other genetic subtypes, a pediatric development strategy and other indications, such as acute lymphocytic leukemia and myelodysplastic syndrome.

 

Clinical collaboration to evaluate tipifarnib and alpelisib in HNSCC – In July, Kura announced a clinical collaboration with Novartis to evaluate the combination of tipifarnib and the PI3Kα inhibitor alpelisib in patients with head and neck squamous cell carcinoma (HNSCC). The Company is now preparing for a Phase 1/2 clinical trial (KURRENT) of tipifarnib in combination with alpelisib in patients who have HRAS- and/or PIK3CA-dependent HNSCC. The initial cohort will include patients who have PIK3CA-dependent HNSCC and the trial is expected to initiate in the fourth quarter of 2021.

 

Nomination of KO-2806 as lead development candidate – Kura has nominated KO-2806 as its lead development candidate in the Company’s next-generation farnesyl transferase inhibitor program. KO-2806 was nominated based on its improved potency, pharmacokinetic and physicochemical properties relative to tipifarnib, and is designed to target innovative biology and address large oncology indications of high unmet need through rational combinations. The Company is now conducting investigational new drug (IND)-enabling studies and expects to submit an IND application for KO-2806 by the end of 2022.

 

Addition of industry veterans to board of directors – Kura recently appointed Carol Schafer and Helen Collins, M.D. to its board of directors. Ms. Schafer brings more than 25 years of experience as a strategic and financial advisor to the leadership teams of growing biopharmaceutical companies, most recently as Vice Chair of Equity Capital Markets at Wells Fargo Securities. Dr. Collins joins with more than 25 years of medical experience, most recently as Chief Medical Officer at Five Prime Therapeutics, where she was responsible for the strategy and execution of

 

 


 

the company’s clinical development plans until its acquisition by Amgen in April 2021.

 

Financial Results and Guidance

 

Research and development expenses for the second quarter of 2021 were $21.1 million, compared to $13.7 million for the second quarter of 2020.

 

General and administrative expenses for the second quarter of 2021 were $12.6 million, compared to $7.5 million for the second quarter of 2020.

 

Net loss for the second quarter of 2021 was $33.7 million, compared to a net loss of $20.5 million for the second quarter of 2020. This included non-cash share-based compensation expense for the second quarter of 2021 of $6.0 million, compared to $2.6 million for the same period in 2020.

 

Cash, cash equivalents and short-term investments totaled $567.5 million as of June 30, 2021, compared with $633.3 million as of December 31, 2020. The cash balance as of June 30 reflects the full repayment of the Company’s debt facility.

 

Operating expenses for the full year 2021 are expected to be in the range of $130 million to $140 million.

 

Net cash used in operating activities for the full year 2021 is expected to be $105 million to $115 million.

 

Management expects that current cash, cash equivalents and short-term investments will be sufficient to fund current operations into 2024.

 

Upcoming Milestones

 

Initiate the KURRENT Phase 1/2 study of tipifarnib in combination with alpelisib in the fourth quarter of 2021.

 

Complete enrollment of 24 evaluable patients in the KOMET-001 Phase 1b expansion cohorts by the first quarter of 2022.

 

Determine the recommended Phase 2 dose of KO-539 by the first quarter of 2022.

 

Submit an IND application for KO-2806 by the end of 2022.

 

Conference Call and Webcast

 

Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT today, August 5, 2021, to discuss the financial results for the second quarter 2021 and provide a corporate update. The live call may be accessed by dialing (877) 516-

 

 


 

3514 for domestic callers and (281) 973-6129 for international callers and entering the conference code: 3171857. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.

 

About Kura Oncology

 

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) and targeting patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed study (AIM-HN) in patients with this devastating disease. In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets of patients, including those who have HRAS- and/or PIK3CA-dependent HNSCC. The Company is also developing a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

 

Forward-Looking Statements

 

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Kura’s product candidates, tipifarnib, KO-539 and KO-2806, progress and expected timing of Kura’s drug development programs and clinical trials and submission of regulatory filings, the presentation of data from clinical trials, plans regarding regulatory filings and future clinical trials, the regulatory approval path for tipifarnib, the strength of Kura’s balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the

 

 


 

negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

KURA ONCOLOGY, INC.

 

Statements of Operations Data

 

(unaudited)

 

(in thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Operating Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

21,074

 

 

$

13,697

 

 

$

41,398

 

 

$

26,272

 

General and administrative

 

 

12,573

 

 

 

7,476

 

 

 

23,145

 

 

 

15,101

 

Total operating expenses

 

 

33,647

 

 

 

21,173

 

 

 

64,543

 

 

 

41,373

 

Other income (expense), net

 

 

(16

)

 

 

686

 

 

 

186

 

 

 

1,676

 

Net loss

 

$

(33,663

)

 

$

(20,487

)

 

$

(64,357

)

 

$

(39,697

)

Net loss per share, basic and diluted

 

$

(0.51

)

 

$

(0.40

)

 

$

(0.97

)

 

$

(0.82

)

Weighted average number of

   shares used in computing net loss

   per share, basic and diluted

 

 

66,282

 

 

 

51,633

 

 

 

66,250

 

 

 

48,522

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

KURA ONCOLOGY, INC.

 

Balance Sheet Data

 

(unaudited)

 

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

June 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Cash, cash equivalents and short-term investments

 

$

567,494

 

 

$

633,320

 

Working capital

 

 

552,342

 

 

 

611,268

 

Total assets

 

 

584,891

 

 

 

647,212

 

Long-term liabilities

 

 

5,050

 

 

 

10,283

 

Accumulated deficit

 

 

(366,859

)

 

 

(302,502

)

Stockholders’ equity

 

 

558,551

 

 

 

610,905

 

 

 


 

 

Contacts

 

Company:

Pete De Spain

Vice President, Investor Relations &

Corporate Communications

(858) 500-8803

pete@kuraoncology.com

 

Investors:

Robert H. Uhl

Managing Director

Westwicke Partners, LLC

(858) 356-5932

robert.uhl@westwicke.com

 

Media:

Jason Spark

Managing Director

Canale Communications

(619) 849-6005

jason@canalecomm.com

 

 

 

GRAPHIC 3 g0iyjjtccmii000001.jpg GRAPHIC begin 644 g0iyjjtccmii000001.jpg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end EX-101.SCH 4 kura-20210805.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 kura-20210805_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 kura-20210805_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 kura-8k_20210805_htm.xml IDEA: XBRL DOCUMENT 0001422143 2021-08-05 2021-08-05 false 0001422143 8-K 2021-08-05 KURA ONCOLOGY, INC. DE 001-37620 61-1547851 12730 High Bluff Drive Suite 400 San Diego CA 92130 (858) 500-8800 false false false false Common Stock, par value $0.0001 per share KURA NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 05, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 05, 2021
Entity Registrant Name KURA ONCOLOGY, INC.
Entity Central Index Key 0001422143
Entity Emerging Growth Company false
Entity File Number 001-37620
Entity Tax Identification Number 61-1547851
Entity Incorporation State Country Code DE
Entity Address, Address Line One 12730 High Bluff Drive
Entity Address, Address Line Two Suite 400
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 500-8800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol KURA
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports kura-8k_20210805.htm kura-20210805.xsd kura-20210805_lab.xml kura-20210805_pre.xml kura-ex991_6.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "kura-8k_20210805.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "kura-8k_20210805.htm" ] }, "labelLink": { "local": [ "kura-20210805_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "kura-20210805_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "kura-20210805.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kura", "nsuri": "http://www.kuraoncology.com/20210805", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "kura-8k_20210805.htm", "contextRef": "C_0001422143_20210805_20210805", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "kura-8k_20210805.htm", "contextRef": "C_0001422143_20210805_20210805", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.kuraoncology.com/20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-21-041588-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-041588-xbrl.zip M4$L#!!0 ( &V!!5.&#FJ(L00 ,T6 1 :W5R82TR,#(Q,#@P-2YX M7+Q:9%1\(RY(#F[].(@\@!F*$\(FU]ZI?"A M0(1XGZY^_^WBG>^#\HFC4[X_ZY\%PT.\-!L,_U$84-13\6_D &K\1. VB( X&_6&#\2M$ M3W".P>VXR=A+>NE9"O$9POVSP=DLZ+#F9/TKP'GTP M$)6_C&%*\1+<$ 89(I"">^OI1W#+4 "N*053+2; % O,GW$2K+0N1#(2UF M)KGL$+3'#$$.=LV2R$T);:(71:=A16P PC7$*2ZH"7[+_2DA)2G"B>B/%NK%M,#3($O(YEG

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end